Created at	Source	Raw Value	Validated value
May 28, 2022, 11:30 a.m.	usa	Participants with Solicited Adverse Events (AEs) - Phase 1;Participants with Solicited Adverse Events (AEs) - Phase 2;Participants with Unsolicited AEs - Phase 2;Safety Laboratory Values (Serum Chemistry, Hematology) - Phase 1;Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs) - Phase 1;Serum IgG Antibody Levels Expressed as GMEUs - Phase 2;Serum IgG Antibody Levels Expressed as GMFRs - Phase 2;Serum IgG Antibody Levels Expressed as SCRs - Phase 2;Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs) - Phase 1;Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1;Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1	Participants with Solicited Adverse Events (AEs) - Phase 1;Participants with Solicited Adverse Events (AEs) - Phase 2;Participants with Unsolicited AEs - Phase 2;Safety Laboratory Values (Serum Chemistry, Hematology) - Phase 1;Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs) - Phase 1;Serum IgG Antibody Levels Expressed as GMEUs - Phase 2;Serum IgG Antibody Levels Expressed as GMFRs - Phase 2;Serum IgG Antibody Levels Expressed as SCRs - Phase 2;Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs) - Phase 1;Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1;Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1
July 23, 2021, 10:30 p.m.	usa	Participants with Solicited Adverse Events (AEs) - Phase 1;Participants with Solicited Adverse Events (AEs) - Phase 2;Participants with Unsolicited AEs - Phase 2;Safety Laboratory Values (Serum Chemistry, Hematology) - Phase 1;Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs) - Phase 1;Serum IgG Antibody Levels Expressed as GMEUs - Phase 2;Serum IgG Antibody Levels Expressed as GMFRs - Phase 2;Serum IgG Antibody Levels Expressed as SCRs - Phase 2;Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs) - Phase 1;Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1	Participants with Solicited Adverse Events (AEs) - Phase 1;Participants with Solicited Adverse Events (AEs) - Phase 2;Participants with Unsolicited AEs - Phase 2;Safety Laboratory Values (Serum Chemistry, Hematology) - Phase 1;Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs) - Phase 1;Serum IgG Antibody Levels Expressed as GMEUs - Phase 2;Serum IgG Antibody Levels Expressed as GMFRs - Phase 2;Serum IgG Antibody Levels Expressed as SCRs - Phase 2;Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs) - Phase 1;Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1
Oct. 26, 2020, 11:31 p.m.	usa	Participants with Solicited Adverse Events (AEs) - Phase 1;Serum IgG Antibody Levels Expressed as GMFRs - Phase 2;Safety Laboratory Values (Serum Chemistry, Hematology) - Phase 1;Participants with Unsolicited AEs - Phase 2;Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1;Serum IgG Antibody Levels Expressed as GMTs - Phase 2;Serum IgG Antibody Levels Expressed as SCRs - Phase 2;Participants with Solicited Adverse Events (AEs) - Phase 2;Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs) - Phase 1;Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs) - Phase 1	Participants with Solicited Adverse Events (AEs) - Phase 1;Serum IgG Antibody Levels Expressed as GMFRs - Phase 2;Safety Laboratory Values (Serum Chemistry, Hematology) - Phase 1;Participants with Unsolicited AEs - Phase 2;Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1;Serum IgG Antibody Levels Expressed as GMTs - Phase 2;Serum IgG Antibody Levels Expressed as SCRs - Phase 2;Participants with Solicited Adverse Events (AEs) - Phase 2;Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs) - Phase 1;Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs) - Phase 1